

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Patent Application of

Nancy M. Lee et al.

Application No.: 10/690,881

Filing Date: October 22, 2003

Title: BIOMARKER PANEL FOR
COLORECTAL CANCER



) **MAIL STOP IDS**

) Group Art Unit: 1636

) Examiner: WALTER SCHLAPKOHL

) Confirmation No.: 8369

**FOURTH
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a Fourth Information Disclosure Statement (IDS) and accompanying form PTO-1449 for the above-identified patent application.

- No additional fee for submission of an IDS is required.
- The fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e), and the fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- Charge _____ to Deposit Account No. 02-4800 for the fee due.
- A check in the amount of _____ is enclosed for the fee due.
- Charge \$ 180.00 to credit card for the fee due. Form PTO-2038 is attached.
- The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Date July 13, 2007

Respectfully submitted,

P.O. Box 1404
Alexandria, VA 22313-1404
858 509 7300


BUCHANAN INGERSOLL & ROONEY LLP

By:


Joseph R. Baker
Registration No. 40900

I hereby certify that this correspondence is being deposited with the United State Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit July 13, 2007


Typed Name: Kim A. Cabello



Patent
Attorney Docket No. 1034516-000006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of) MAIL STOP
Nancy M. Lee et al.)) Group Art Unit: 1636
Application No.: 10/690,880)) Examiner: WALTER SCHLAPKOHL
Filed: October 22, 2003)) Confirmation No.: 8369
For: BIOMARKER PANEL FOR))
COLORECTAL CANCER))
))
))

FOURTH INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, copies of the listed U.S. patents and U.S. patent application publications are not enclosed since it is no longer required.

The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), a statement is enclosed.

A fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) is enclosed.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

180.00 op

07/19/2007 WABDEL R1 00000006 10690880

01 FEE:1806


FOURTH Information Disclosure Statement
Application No. 10/690,880
Attorney Docket No. 1034516-000006
Page 2

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY LLP

Date: July 13, 2007

By: 
Joseph R. Baker, Jr.
Registration No. 40,900

P.O. Box 1404
Alexandria, VA 22313-1404
858 509 7300

**FOURTH
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Sheet 1 of

JUL 18 2007

Application Number	10/690,880
Filing Date	October 22, 2003
First Named Inventor	Nancy M. Lee
Examiner Name	Walter Schlapkohl
Attorney Docket No.	1034516-000006

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	20060121495	A1	Shuber	06-08-2006
	20050260638	A1	Shuber	11-24-2005
	20040259101	A1	Shuber	12-23-2004
	20040043467	A1	Shuber	03-04-2004
	20040014104	A1	Shuber	01-22-2004
	20020164631	A1	Shuber	11-07-2002
	20020119472	A1	Lapidus	08-29-2002
	6,964,846		Shuber	11-15-2005
	6,919,174		Shuber	07-19-2005
	6,586,177		Shuber	0-01-2003
	6,406,857		Shuber	06-18-2002
	6,303,304		Shuber	11-16-2001
	6,268,136		Shuber	07-31-2001
	5,952,178		Lapidus	09-14-1999
	5,741,650		Lapidus	04-21-1998

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS					Cited in Spec
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog; etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Clark et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. (Oncogene, vol 19, pp 4125-4133, published 2000)
	Clark et al. Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. (Biochemical Pharmacology, vol 62, pp 1311-1336, published 2001)
	GeneBank® accession number M94582 [online], publicly available Apr. 27, 1993 [retrieved on July 12, 2007], retrieved from the internet <URL:www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=186377>
	GeneBank® accession number NM_006238 [online], publicly available Jul 13, 1999 [retrieved on July 12, 2007], retrieved from the internet <URL:www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?5453939:OLD02:501339>
	Korfhage et al., R&D Department , "Critical Factors For Successful Microarray And Real-Time Analyses", Issue No. 5, QIAGEN GmbH, Hilden, Germany 2002

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
#1001737